The Role of Colchicine in Reducing The Rate of Myocardial Reperfusion Injury
Status:
Enrolling by invitation
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to investigate the role of colchicine in reducing the rate
of myocardial reperfusion injury in patients with ST-elevation myocardial infarction after
primary percutaneous coronary intervention. The main questions it aims to answer are:
- Does colchicine reduce the rate of myocardial reperfusion injury ?
- Does colchicine reduce the concentration of markers of myocardial reperfusion injury
(NLRP3, ASC, caspase, and troponin) ?
Participants will
- Be grouped into intervention group and control group blindly. Patients in the
intervention group receive loading dose of colchicine 1 x 2 mg followed by colchicine 2
x 0,5 mg daily for two consecutive days. Patients in the control group receive loading
dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two
consecutive days.
- Undergo peripheral blood vein examination before primary percutaneous coronary
intervention, after primary percutaneous coronary intervention, 24 hour after primary
percutaneous coronary intervention, and 48 hour after primary percutaneous coronary
intervention.
Researchers will compare intervention group and control group to see if colchicine reduces
the rate of myocardial reperfusion injury and reduces the concentration of markers of
myocardial reperfusion injury (NLRP3, ASC, caspase, and troponin) in patients with
ST-elevation myocardial infarction after primary percutaneous coronary intervention.